These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 7480380)

  • 81. Glycine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label, pilot study.
    Rosse RB; Theut SK; Banay-Schwartz M; Leighton M; Scarcella E; Cohen CG; Deutsch SI
    Clin Neuropharmacol; 1989 Oct; 12(5):416-24. PubMed ID: 2611765
    [TBL] [Abstract][Full Text] [Related]  

  • 82. The effect of anti-psychotic medication and diagnostic criteria on distractibility in schizophrenia.
    Oltmanns TF; Ohayon J; Neale JM
    J Psychiatr Res; 1978; 14(1-4):81-91. PubMed ID: 31471
    [No Abstract]   [Full Text] [Related]  

  • 83. Attentional predictors of clinical change during neuroleptic treatment in schizophrenia.
    Serper MR; Davidson M; Harvey PD
    Schizophr Res; 1994 Aug; 13(1):65-71. PubMed ID: 7947417
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Navane versus Haldol. Treatment of acute organic mental syndromes in the general hospital.
    Peterson LG; Bongar B
    Gen Hosp Psychiatry; 1989 Nov; 11(6):412-7. PubMed ID: 2806891
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Cognitive subprocesses and schizophrenia. B. Maze tasks.
    Krieger S; Lis S; Gallhofer B
    Acta Psychiatr Scand Suppl; 2001; (408):28-41. PubMed ID: 11730071
    [TBL] [Abstract][Full Text] [Related]  

  • 86. [Cognitive functions and remission].
    Sarfati Y
    Encephale; 2005 Dec; 31 Pt 2():S21-3. PubMed ID: 16462631
    [No Abstract]   [Full Text] [Related]  

  • 87. Information-processing abnormalities as neuropsychological vulnerability indicators for schizophrenia.
    Nuechterlein KH; Dawson ME; Green MF
    Acta Psychiatr Scand Suppl; 1994; 384():71-9. PubMed ID: 7879647
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Effect of concurrent distraction on communication failures in schizophrenic patients. II. Medication status correlations.
    Moskowitz J; Davidson M; Harvey PD
    Schizophr Res; 1991 Sep; 5(2):153-9. PubMed ID: 1681891
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Antipsychotic medications: clinical use and effectiveness.
    Cordoba OA
    Hosp Pract (Off Ed); 1981 Dec; 16(12):99-101, 104, 108. PubMed ID: 6118323
    [No Abstract]   [Full Text] [Related]  

  • 90. Treatment-refractory schizophrenia.
    Buckley PF; Wiggins LD; Sebastian S; Singer B
    Curr Psychiatry Rep; 2001 Oct; 3(5):393-400. PubMed ID: 11559476
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Effect of thiothixene upon the higher nervous activity in chronic schizophrenics.
    Saarma J; Saarma M; Sild L; Tikk P
    Int Pharmacopsychiatry; 1974; 9(2):109-17. PubMed ID: 4851705
    [No Abstract]   [Full Text] [Related]  

  • 92. Somatic profiles in chronic schizophrenia.
    Howard JS
    Psychosomatics; 1976; 17(1):26-31. PubMed ID: 5744
    [No Abstract]   [Full Text] [Related]  

  • 93. The effects of an antipsychotic medication on the classroom behavior of four schizophrenic male children.
    Simpson RL
    J Autism Child Schizophr; 1977 Dec; 7(4):349-58. PubMed ID: 340450
    [TBL] [Abstract][Full Text] [Related]  

  • 94. When do we become more distractible? Progressive evolution of different components of distractibility from early to late adulthood.
    Hoyer RS; Abdoun O; Riedinger M; Bouet R; Elshafei A; Bidet-Caulet A
    J Exp Psychol Gen; 2023 Dec; 152(12):3403-3417. PubMed ID: 37589702
    [TBL] [Abstract][Full Text] [Related]  

  • 95. A controlled study of SK&F 14336 in acute schizophrenia.
    Bishop MP; Gallant DM
    J Clin Pharmacol J New Drugs; 1967; 7(6):342-7. PubMed ID: 5234899
    [No Abstract]   [Full Text] [Related]  

  • 96. An fMRI study of functional abnormalities in the verbal working memory system and the relationship to clinical symptoms in chronic schizophrenia.
    Hashimoto R; Lee K; Preus A; McCarley RW; Wible CG
    Cereb Cortex; 2010 Jan; 20(1):46-60. PubMed ID: 19395526
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Distractibility in schizophrenia.
    Bergman A; O'Brien J; Osgood G; Cornblatt B
    Psychiatry Res; 1995 Jul; 57(2):131-40. PubMed ID: 7480380
    [TBL] [Abstract][Full Text] [Related]  

  • 98. The effect of antipsychotic medication on relative cerebral blood perfusion in schizophrenia: assessment with technetium-99m hexamethyl-propyleneamine oxime single photon emission computed tomography.
    Miller DD; Rezai K; Alliger R; Andreasen NC
    Biol Psychiatry; 1997 Mar; 41(5):550-9. PubMed ID: 9046987
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Thiothixene and trifluoperazine in acutely disturbed schizophrenic patients.
    Ahmad SH; Hasan KZ
    J Pak Med Assoc; 1977 Apr; 27(4):313-6. PubMed ID: 411951
    [TBL] [Abstract][Full Text] [Related]  

  • 100. The relationship of neuropsychological test performance with the PANSS in antipsychotic naïve, first-episode psychosis patients.
    Good KP; Rabinowitz J; Whitehorn D; Harvey PD; DeSmedt G; Kopala LC
    Schizophr Res; 2004 May; 68(1):11-9. PubMed ID: 15037335
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.